$ENTB Zander Therapeutics is a wholly owned subsid
Post# of 6702
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (RGBP) (RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (RGBP), Entest BioMedical Inc. (ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
http://finance.yahoo.com/news/entest-biomedic...NlYwNzYw--